A second biosimilar rival to Sanofi’s Lantus (insulin glargine) has been approved by the US Food and Drug Administration in the form of Eli Lilly’s Rezvoglar (insulin glargine-aglr) 3ml pre-filled pens.
Will Eli Lilly’s Rezvoglar Be Able To Compete With Interchangeable Semglee?
FDA Approves Second Insulin Glargine Biosimilar Rival To Lantus
The FDA has approved the second biosimilar insulin glargine rival to Lantus, in the form of Eli Lilly’s Rezvoglar. However, Viatris’ recently relaunched Semglee version has an interchangeability designation on its side.
More from Biosimilars
More from Products
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.